0933 GMT - Smith & Nephew's ambitious new midterm revenue growth target implies significant upside to consensus expectations at the mid-point, RBC Capital Markets analysts say in a note. The medical technology company targets 6%-7% top-line compound annual growth rate to 2028 with 9%-10% trading profit CAGR. The revenue growth target implies significant upside to consensus revenue CAGR of 5.2%. "Given the significant step up from historical performance required to achieve this target, we remain nervous until the company can demonstrate reliably that it can generate this growth," RBC says. Shares are up 1.1% at 1,279 pence. (anthony.orunagoriainoff@dowjones.com)

(END) Dow Jones Newswires

December 08, 2025 04:34 ET (09:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.